Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22561
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMacdonald, Joanna-
dc.contributor.authorHenri, Justin-
dc.contributor.authorJamieson, Adelaide-
dc.contributor.authorDenoyer, Delphine-
dc.contributor.authorBurvenich, Ingrid J G-
dc.contributor.authorPouliot, Normand-
dc.contributor.authorShigdar, Sarah-
dc.date2020-02-06-
dc.date.accessioned2020-02-11T01:18:15Z-
dc.date.available2020-02-11T01:18:15Z-
dc.date.issued2020-04-
dc.identifier.citationNucleic Acid Therapeutics 2020; 30(2): 117-128en
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22561-
dc.description.abstractThe prognosis for breast cancer patients diagnosed with brain metastases is poor, with survival time measured merely in months. This can largely be attributed to the limited treatment options capable of reaching the tumor as a result of the highly restrictive blood-brain barrier (BBB). While methods of overcoming this barrier have been developed and employed with current treatment options, the majority are highly invasive and nonspecific, leading to severe neurotoxic side effects. A novel approach to address these issues is the development of therapeutics targeting receptor-mediated transport mechanisms on the BBB endothelial cell membranes. Using this approach, we intercalated doxorubicin (DOX) into a bifunctional aptamer targeting the transferrin receptor on the BBB and epithelial cell adhesion molecule (EpCAM) on metastatic cancer cells. The ability of the DOX-loaded aptamer to transcytose the BBB and selectively deliver the payload to EpCAM-positive tumors was evaluated in an in vitro model and confirmed for the first time in vivo using the MDA-MB-231 breast cancer metastasis model (MDA-MB-231Br). We show that colocalized aptamer and DOX are clearly detectable within the brain lesions 75 min postadministration. Collectively, results from this study demonstrate that through intercalation of a cytotoxic drug into the bifunctional aptamer, a therapeutic delivery vehicle can be developed for specific targeting of EpCAM-positive brain metastases.en
dc.language.isoeng-
dc.subjectaptameren
dc.subjectblood brain barrieren
dc.subjectcanceren
dc.subjecttherapeuticen
dc.titleBifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to Epithelial Cell Adhesion Molecule-Positive Tumor Cells.en
dc.typeJournal Articleen
dc.identifier.journaltitleNucleic Acid Therapeuticsen
dc.identifier.affiliationCentre for Molecular and Medical Research, Deakin University, Geelong, Australiaen
dc.identifier.affiliationDepartment of Pathology, The University of Melbourne, Parkville, Australiaen
dc.identifier.affiliationSchool of Medicine, Deakin University, Geelong, Australiaen
dc.identifier.affiliationMatrix Microenvironment and Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Australiaen
dc.identifier.doi10.1089/nat.2019.0807en
dc.type.contentTexten
dc.identifier.orcid0000-0001-8932-5116en
dc.identifier.pubmedid32027209-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.